Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

United Therapeutics (UTHR) delivered earnings and revenue surprises of +6.60% and -2.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.